Cargando…
Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis
OBJECTIVES: To determine the safety, pharmacokinetics (PK), and immunogenicity of the recombinant human monoclonal antibody MOR103 to granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with multiple sclerosis (MS) with clinical or MRI activity. METHODS: In this 20-week, randomized...
Autores principales: | Constantinescu, Cris S., Asher, Aliya, Fryze, Waldemar, Kozubski, Wojciech, Wagner, Frank, Aram, Jehan, Tanasescu, Radu, Korolkiewicz, Roman P., Dirnberger-Hertweck, Maren, Steidl, Stefan, Libretto, Susan E., Sprenger, Till, Radue, Ernst W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4442097/ https://www.ncbi.nlm.nih.gov/pubmed/26185773 http://dx.doi.org/10.1212/NXI.0000000000000117 |
Ejemplares similares
-
Increased IL-2 and Reduced TGF-β Upon T-Cell Stimulation are Associated with GM-CSF Upregulation in Multiple Immune Cell Types in Multiple Sclerosis
por: Aram, Jehan, et al.
Publicado: (2020) -
Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Jurczak, W, et al.
Publicado: (2018) -
Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis
por: Aram, Jehan, et al.
Publicado: (2018) -
CSF lymphocytic pleocytosis does not predict a less favourable long-term prognosis in MS
por: Astbury, Lauren, et al.
Publicado: (2022) -
GM-CSF in inflammation
por: Hamilton, John A.
Publicado: (2019)